Business Wire (Tue, 4:30AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
3,268 people get BIIB articles and Market Currents by email alert.
Get email alerts on BIIB »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Business Wire (May 13, 2013)
-
-
-
-
-
-
-
-
-
-
Business Wire (Apr 25, 2013)
-
-
-
-
-
-
-
Tecfidera Raises The Bar For Biogen IdecBrian L. Wilson • Mon, Apr 1 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Biogen: A 'Decimated' Pipeline?Derek Lowe • Tue, Jan 17, 2012 -
Biogen Idec: Q3 Clues To ValueWilliam Meyers • Thu, Nov 3, 2011
-
Biogen Idec: Fairly Priced With A Healthy Balance SheetRon Sommer • Mon, Sep 12, 2011
-
Biogen Idec's CEO Hosts 2012 Analyst Day (Transcript)Tue, Jun 12, 2012 • 1 Comment
-
Biogen Idec's CEO Discusses Q4 2011 Results - Earnings Call TranscriptTue, Jan 31, 2012
-
Biogen Idec's CEO Discusses Q3 2011 Results - Earnings Call TranscriptFri, Oct 28, 2011
-
Biogen Idec Inc. - Special CallWed, Oct 26, 2011
-
Biogen Idec's CEO Discusses Q2 2011 Results - Earnings Call TranscriptTue, Jul 26, 2011
-
Biogen Idec's CEO Discusses Q1 2011 Results - Earnings Call TranscriptThu, Apr 21, 2011
-
Biogen Idec CEO Discusses Q3 2010 Results - Earnings Call TranscriptTue, Oct 26, 2010
-
Biogen Idec Inc. Q2 2010 Earnings Call TranscriptTue, Jul 20, 2010
-
Biogen Idec, Inc. Q1 2010 Earnings Call TranscriptTue, Apr 20, 2010
-
Biogen Idec, Inc. Q4 2009 Earnings Call TranscriptTue, Feb 9, 2010 • 1 Comment
-
Biogen Idec Inc. Q3 2009 Earnings Call TranscriptTue, Oct 20, 2009
-
Biogen Idec Inc., Q2 2009 Earnings Call TranscriptThu, Jul 16, 2009
-
Business Wire (Tue, 4:30AM)
-
at CNBC.com (May 14, 2013)
-
Business Wire (May 13, 2013)
-
at CNBC.com (May 9, 2013)
-
at MarketWatch.com (May 9, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at MarketWatch.com (Apr 26, 2013)
-
at CNBC.com (Apr 25, 2013)
-
at MarketWatch.com (Apr 25, 2013)
-
Business Wire (Apr 25, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at MarketWatch.com (Apr 22, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at CNBC.com (Apr 20, 2013)
-
at CNBC.com (Apr 18, 2013)
-
at CNBC.com (Apr 15, 2013)
-
at MarketWatch.com (Apr 15, 2013)
-
at CNBC.com (Apr 12, 2013)
-
at CNBC.com (Apr 11, 2013)
BIIB vs. ETF Alternatives
Company Description
Biogen Idec is a global biotechnology company that creates new standards of care in therapeutic areas with high unmet medical needs. Our business strategy is focused on discovering and developing first-in-class or best-in-class products that we can deliver to specialty markets globally.... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 21, 1:50 PM Biogen (BIIB +3.6%) submits Biologics License Application to the FDA for the approval of its injectable drug candidate Plegridy for the treatment of multiple sclerosis. The company says the application is supported by data from year one of a two year Phase 3 study which "met all primary and secondary endpoints." In March, BIIB said the drug cut annual relapse rates by 36% and analysts say it could generate revenue of $318M by 2017. (PR) Comment! [Healthcare, On the Move]
- Monday, May 13, 4:11 PM Biogen-Idec (BIIB +4.5%) finishes the day solidly higher after announcing that the FDA has accepted its Biologics License Application for the marketing approval of Elocate, a treatment for hemophilia A. With the acceptance BIIB now has product candidates under review for both hemophilia A and B. Comment! [Healthcare, On the Move]
- Monday, April 29, 10:28 AM Biogen Idec (BIIB +4.9%) gains this morning after giving an update on Tecfidera prescription performance. According to data, the drug has already garnered nearly 8% of the multiple sclerosis market through the week ended April 19, with prescriptions up 120% over the prior week. By comparison, Novartis' (NVS) Gilenya saw a market share drop to 6%. RBC sees performance on track to meet quarterly sales expectations. Comment! [Healthcare, On the Move]
- Thursday, April 25, 7:47 AM More on Biogen's (BIIB) Q1: Revenue gains driven by 13% Y/Y growth of AVONEX. RITUXAN revenues reduced by $42M for damages awarded to Genentech. FAMPRYA and FUMADERM sales up 25%. Corporate partner revenues were $22M versus $3M in the comparable period last year. FY2013 guidance: revenue growth of between 16-18% and non-GAAP EPS of between $7.80-7.90. Analysts expect EPS of $7.79. Shares +2.8% premarket. (PR) Comment! [Healthcare, Earnings, On the Move]
- Thursday, April 25, 6:31 AM Biogen Idec (BIIB): Q1 EPS of $1.97 beats by $0.36. Revenue of $1.4B (+10% Y/Y) misses by $0.01B. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, April 25, 12:05 AM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
- Wednesday, April 24, 5:30 PM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
- Tuesday, April 23, 7:51 AM Isis Pharmaceuticals (ISIS) initiates a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. The company will get $3.5M from Biogen (BIIB) upon dosing the first infant next month. Comment! [Healthcare]
- Monday, April 22, 12:12 PM Biogen (BIIB +5.8%) rises after ICI analyst Mark Schoenebaum says the company's Tecfidera multiple sclerosis drug seems to be "crushing" its competitors. Following just a week on the market, Tecfidera's sales have achieved the same level that Novartis' (NVS) Gilenya reached after three months. However, Schoenebaum warns that it's still too early to make any definitive conclusions about Tecfidera. Comment! [Healthcare, On the Move]
- Wednesday, April 17, 5:15 PM S&P takes Biogen (BIIB) further into investment grade territory, raising the firm's corporate credit rating to A- with a stable outlook. Three approved multiple sclerosis treatments and "no significant patent expirations in the intermediate term" equate to "minimal" financial risk. Comment! [Healthcare]
- Tuesday, April 16, 2:05 PM Biogen Idec (BIIB +1.2%) and Roche's (RHHBY.PK) Genetech lose their appeal made in a patent infringement case against GlaxoSmithKline (GSK -0.1%). The Court upheld the interpretation of a BIIB patent covering the cancer drug Arzerra, ruling that GSK didn't infringe upon the patent. Comment! [Healthcare]
- Friday, April 12, 10:59 AM Elan's (ELN -1.3%) shareholders have overwhelmingly approved a plan to buy back $1B in stock following the sale of Tsabri to Biogen Idec (BIIB +2.4%), as speculation mounts that an earlier takeover indication by Royalty Pharma might be sweetened. Royalty approached ELN in February with an $11 per share potential offer, valuing the company at $6.55B, which was rejected by ELN. Last week, Ireland's Takeover Panel told the pharmaceutical investor to either step up and announce an official takeover offer for the company by May 10, or walk away. Comment! [Healthcare, Global & FX, M&A]
- Friday, April 12, 10:33 AM Biogen Idec (BIIB +4%) moves higher after BofA/ Merrill Lynch upgrades the shares to Buy from Neutral. Price target raised to $246 from $187. Comment! [On the Move, Healthcare]
- Tuesday, April 2, 6:08 PM Biogen Idec (BIIB) completes its purchase of Elan's (ELN) interest in Tysabri, gaining full strategic, commercial and decision-making rights to the relapsing MS drug treatment. [BIIB plans to give further details and updated financial guidance during it's upcoming Q1 earnings announcement. Shares +0.3% AH. Comment! [Healthcare, M&A]
- Thursday, March 28, 4:24 PM Biotech ETFs close at or near all-time highs as heavyweights Amgen (AMGN +2.4%), Biogen (BIIB +5.2%), Celgene (CELG +2.4%) and Gilead Sciences (GILD +2.5%) make new 52-week highs going into the holiday weekend. 1 Comment [Healthcare]
- Wednesday, March 27, 4:12 PM Shares of Teva (TEVA -1.2%) close lower today on the back of Biogen's (BIIB +3%) earlier announcement of FDA approval for its MS capsule Tecfidera. Earlier in the week, TEVA had announced its own successful results from Phase III testing for its Multiple Sclerosis drug Laquinimod. Comment! [Healthcare, Global & FX, On the Move]
-
Kenneth Hackel
Last week CT Capital sold $BIIB after tripling and bought #QCOR at $30.96, up 30% in a week. - View all 0 replies
-
Ryan Mallory
Fuinhaz Setups for April 25 2013 | $AKAM $ALNX $BIIB $CROX $INFN $LSI $PERI $YNDX | SharePlanner http://bit.ly/12Kc6ip - View all 0 replies
-
- View all 1 replies
-
-
Jim Van Meerten
$BIIB - 96% Barchart technical buy signals - 11 new highs and up 15.13% in the last month - Relative Strength Index 78.77% - View all 0 replies
-
Michael Bryant
Biogen Idec ($BIIB) is surging higher. Still more bight days ahead for the biotech giant. http://yhoo.it/XWT1oi;c= - View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
Jim Van Meerten
$BIIB - 96% Barchart technical buy signal - 11 new highs and up 8.90% in the last month - Relative Strength Index 70.31% - View all 0 replies
-
Tony Kau
$BIIB exhausted - good credit spread play: Apr 190/195 calls for $0.80; expected return: 11%! http://ow.ly/i/1GyN8 http://ow.ly/iVHJ3 - View all 2 replies
-
-
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 1 replies
-
-
Tony Kau
$BIIB exhausted - good credit spread play: Apr 190/195 calls for $0.80; expected return: 11%! http://ow.ly/i/1GyN8 http://ow.ly/iVHJ3 - View all 2 replies
-
-
-
- View all 3 replies
-
FortSumter: an appointment in the Obama administration. Renewal, that is. Thanks for the list. -
-
- View all 3 replies
-
-
-
- View all 5 replies
-
-
-
- View all 4 replies
-
Iron Hamster: Any idea why SCL is dropping? Everything I'm reading says it's a buy and it's too early for profit taking, yet it's down on an up day. -
-
- View all 1 replies
-
-
- View all 1 replies
-
-
Justin M. Hall
8/6/11 12A ET: (VRUS, ALXN, BIIB, ILMN, PRGO) BIOTECH CORRECTION Called in June 2011 => Were You Paying Attention? http://seekingalpha.com/p/4bsg - View all 1 replies
-
-
- View all 1 replies
-
cowpieTX: i manage a diagnostic imaging center for a 17b market cap company. the cuts are real and they are deep. tread carefully.